ONC
NASDAQBeOne Medicines Ltd.
News25/Ratings7
News · 26 weeks95-23%
2026-03-012026-08-23
Mix6990d
- Insider45(65%)
- Other11(16%)
- SEC Filings11(16%)
- Analyst1(1%)
- Earnings1(1%)
Latest news
25 items- PRBeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEATEVIMBRA plus ZIIHERA and chemotherapy is the first and only immunotherapy-based regimen to deliver more than two years of median OS in first-line HER2+ GEA, regardless of PD-L1 status Regimen poised to become standard of care in this difficult-to-treat disease. BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of adult patients with unresectable locally advanced or metastatic HER2-positive (HER2+) gas
- INSIDERSVP, General Counsel Lee Chan Henry exercised 2,666 units of American Depositary Shares at a strike of $191.37 and sold $959,760 worth of American Depositary Shares (2,666 units at $360.00) as part of a pre-agreed trading plan (SEC Form 4)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERChief Executive Officer Oyler John sold $86,480,472 worth of American Depositary Shares (240,810 units at $359.12) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- SECSEC Form 144 filed by BeOne Medicines Ltd.144 - BeOne Medicines Ltd. (0001651308) (Subject)
- PRBeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization CollaborationClinical collaboration enables novel combinations of select BeOne oncology assets with four Revolution Medicines clinical-stage RAS(ON) inhibitors for RAS-addicted cancers Regional rights agreement provides BeOne with exclusive development and commercialization rights to four Revolution Medicines clinical assets in select Asian markets BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, and Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations inco
- INSIDERChief Financial Officer Rosenberg Aaron sold $361,811 worth of American Depositary Shares (1,157 units at $312.71), closing all direct ownership in the company (SEC Form 4) to satisfy tax liability4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- SECSEC Form 10-Q filed by BeOne Medicines Ltd.10-Q - BeOne Medicines Ltd. (0001651308) (Filer)
- SECBeOne Medicines Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - BeOne Medicines Ltd. (0001651308) (Filer)
- PRBeOne Medicines Announces Second Quarter 2026 Financial Results and Business UpdatesTotal global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year BRUKINSA (zanubrutinib) global revenues of $1.2 billion for the second quarter, an increase of 31% from the prior year Diluted GAAP Earnings per American Depository Share (ADS) of $2.05 for the second quarter; non-GAAP diluted Earnings per ADS of $3.84 for the second quarter Raised 2026 total revenue guidance to $6.6 to $6.8 billion; GAAP operating income of $1 to $1.1 billion, non-GAAP operating income of $1.7 to $1.8 billion BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced financial results and corporate updates from the
- INSIDERSVP, General Counsel Lee Chan Henry sold $337,932 worth of American Depositary Shares (1,044 units at $323.69), closing all direct ownership in the company (SEC Form 4) to cover taxes4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERSVP, General Counsel Lee Chan Henry exercised 1,669 units of American Depositary Shares at a strike of $191.58 and sold $542,425 worth of American Depositary Shares (1,669 units at $325.00) as part of a pre-agreed trading plan (SEC Form 4)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- PRBeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines$300 million expansion of flagship manufacturing facility in Hopewell, New Jersey, adds small molecule manufacturing capacity, enhancing U.S. domestic production capabilities Creates 120 new full-time jobs to support U.S. manufacturing of BeOne's innovative oncology medicines and deep clinical pipeline BeOne Medicines, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced a $300 million expansion of its flagship clinical and commercial-stage manufacturing and research and development center at the Princeton West Innovation Campus in Hopewell, New Jersey, bringing total U.S. manufacturing investment to more than $1 billion. The expansion will increase B
- INSIDERChief Executive Officer Oyler John sold $34,590,855 worth of American Depositary Shares (109,713 units at $315.28) as part of a pre-agreed trading plan and exercised 33,990 units of American Depositary Shares at a strike of $119.96, closing all direct ownership in the company (SEC Form 4)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERChief Executive Officer Oyler John sold $20,163,907 worth of American Depositary Shares (64,628 units at $312.00) as part of a pre-agreed trading plan and exercised 64,628 units of American Depositary Shares at a strike of $119.96 (SEC Form 4)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERChief Executive Officer Oyler John exercised 283,154 units of American Depositary Shares at a strike of $145.28 and sold $89,351,598 worth of American Depositary Shares (283,154 units at $315.56) as part of a pre-agreed trading plan (SEC Form 4)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- PRBeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, will report its second quarter 2026 financial results on Wednesday, August 5, 2026 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global
- INSIDERChief Executive Officer Oyler John sold $44,626,424 worth of American Depositary Shares (145,861 units at $305.95) as part of a pre-agreed trading plan and exercised 133,600 units of American Depositary Shares at a strike of $54.06, closing all direct ownership in the company (SEC Form 4)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERChief Executive Officer Oyler John exercised 60,218 units of American Depositary Shares at a strike of $36.90 and sold $18,256,808 worth of American Depositary Shares (60,218 units at $303.18) as part of a pre-agreed trading plan (SEC Form 4)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- SECSEC Form 144 filed by BeOne Medicines Ltd.144 - BeOne Medicines Ltd. (0001651308) (Subject)
- ANALYSTBeOne Medicines upgraded by Jefferies with a new price targetJefferies upgraded BeOne Medicines from Hold to Buy and set a new price target of $380.00
- INSIDERSVP, General Counsel Lee Chan Henry sold $200,833 worth of American Depositary Shares (664 units at $302.46) as part of a pre-agreed trading plan and exercised 664 units of American Depositary Shares at a strike of $191.56 (SEC Form 4)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- SECSEC Form 144 filed by BeOne Medicines Ltd.144 - BeOne Medicines Ltd. (0001651308) (Subject)
- SECSEC Form 144 filed by BeOne Medicines Ltd.144 - BeOne Medicines Ltd. (0001651308) (Subject)
- PRBeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell LymphomaFoundational BTKi BRUKINSA plus rituximab reduced the risk of progression or death by 43% versus bendamustine plus rituximab (HR=0.57; p<0.0001), meeting the primary endpoint of PFS MANGROVE is the first Phase 3 trial to advance a new chemotherapy-free standard in frontline MCL, potentially allowing patients freedom from the burden of years of infusions Full results from MANGROVE, including efficacy and safety, will be presented at an upcoming medical meeting; global regulatory submissions are planned for 2H 2026 BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-30
- SECBeOne Medicines Ltd. filed SEC Form 8-K: Other Events8-K - BeOne Medicines Ltd. (0001651308) (Filer)
ONC FAQ
6 questionsWhere does ONC stock trade?
BeOne Medicines Ltd. (ONC) is listed on NASDAQ.What sector and industry is ONC in?
BeOne Medicines Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did BeOne Medicines Ltd. go public?
BeOne Medicines Ltd. (ONC) completed its IPO in 2016.What are analysts saying about ONC?
BeOne Medicines Ltd. has had 7 recent analyst actions on file. The most recent action was from Jefferies: Buy on 2026-07-13.What companies are similar to ONC?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ONC side-by-side with any of them on Quantisnow.How can I track ONC on Quantisnow?
Quantisnow aggregates BeOne Medicines Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ONC to receive live email and push alerts on every new disclosure.